ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

WuXi Will Advance Lilly Drug In China

by Jean-François Tremblay
November 23, 2015 | APPEARED IN VOLUME 93, ISSUE 46

The pharmaceutical services firm WuXi AppTec will develop for the China market an unspecified Eli Lilly & Co. compound being tested as a treatment for the blood disorder dyslipidemia. Under the agreement, WuXi will register, develop, and manufacture the drug in China, where as many as 12 million patients could use it to reduce their risk of cardiovascular events. WuXi is currently building a commercial-scale drug chemical manufacturing site in Changzhou, China.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment